Paradigm Gets US Ethics Approval for Phase 3 Trial of Knee Osteoarthritis Drug Candidate

MT Newswires Live

2025/05/15

Paradigm Biopharmaceuticals (ASX:PAR) said it received US ethics approval to start a phase 3 trial of injectable pentosan polysulfate sodium (iPPS) for the potential treatment of knee osteoarthritis, according to a Thursday filing with the Australian bourse.

The approval, granted by a centralized institutional review board, allows the company to start the trial across the US, the filing said.

The first patient is expected to be enrolled in the third quarter of the year, the filing added.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2535887129"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535887129\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535887129?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-15 08:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535887129","market":"us","top_or_hot":-1,"title":"Paradigm Gets US Ethics Approval for Phase 3 Trial of Knee Osteoarthritis Drug Candidate","media":"MT Newswires Live","content":"<html><body><p> Paradigm Biopharmaceuticals (ASX:PAR) said it received US ethics approval to start a phase 3 trial of injectable pentosan polysulfate sodium (iPPS) for the potential treatment of knee osteoarthritis, according to a Thursday filing with the Australian bourse.</p><p>The approval, granted by a centralized institutional review board, allows the company to start the trial across the US, the filing said.</p><p>The first patient is expected to be enrolled in the third quarter of the year, the filing added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Paradigm Gets US Ethics Approval for Phase 3 Trial of Knee Osteoarthritis Drug Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nParadigm Gets US Ethics Approval for Phase 3 Trial of Knee Osteoarthritis Drug Candidate\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-05-15 08:04</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Paradigm Biopharmaceuticals (ASX:PAR) said it received US ethics approval to start a phase 3 trial of injectable pentosan polysulfate sodium (iPPS) for the potential treatment of knee osteoarthritis, according to a Thursday filing with the Australian bourse.</p><p>The approval, granted by a centralized institutional review board, allows the company to start the trial across the US, the filing said.</p><p>The first patient is expected to be enrolled in the third quarter of the year, the filing added.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PAR.AU","symbol_name":"PARADIGM BIOPHARMACEUTICALS","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2535887129","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535887129","pubTimestamp":1747267448,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Paradigm Biopharmaceuticals  said it received US ethics approval to start a phase 3 trial of injectable pentosan polysulfate sodium  for the potential treatment of knee osteoarthritis, according to a Thursday filing with the Australian bourse.The approval, granted by a centralized institutional review board, allows the company to start the trial across the US, the filing said.The first patient is expected to be enrolled in the third quarter of the year, the filing added.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PAR.AU":"PARADIGM BIOPHARMACEUTICALS","BK7067":"生物科技","BK7508":"医药生物股"},"translate_title":"Paradigm膝骨关节炎候选药物3期试验获得美国伦理批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PAR.AU":0.9},"content_text":"Paradigm Biopharmaceuticals (ASX:PAR) said it received US ethics approval to start a phase 3 trial of injectable pentosan polysulfate sodium (iPPS) for the potential treatment of knee osteoarthritis, according to a Thursday filing with the Australian bourse.The approval, granted by a centralized institutional review board, allows the company to start the trial across the US, the filing said.The first patient is expected to be enrolled in the third quarter of the year, the filing added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}